Premium
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes PR Newswire WILMINGTON, Del. and WALTHAM, Mass., Jan. 15, 2025...
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass., Jan. 13, 2025 – Launched Revuforj®...
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 7, 2025 NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass., Jan. 7, 2025 WALTHAM, Mass., Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Jan. 3, 2025 WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals...
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial PR Newswire WALTHAM, Mass...
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting PR Newswire WALTHAM...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.21 | 9.20152091255 | 13.15 | 14.73 | 13.15 | 2016712 | 14.1218121 | CS |
| 4 | 1.82 | 14.5135566188 | 12.54 | 14.73 | 12.06 | 1929532 | 13.60036951 | CS |
| 12 | -4.74 | -24.8167539267 | 19.1 | 22.5 | 12.06 | 2410599 | 14.94834091 | CS |
| 26 | -6.59 | -31.4558472554 | 20.95 | 23.37 | 12.06 | 1584734 | 16.49736565 | CS |
| 52 | -5.87 | -29.0163124073 | 20.23 | 25.34 | 12.06 | 1327474 | 18.6549376 | CS |
| 156 | -0.52 | -3.49462365591 | 14.88 | 29.86 | 11.215 | 1075042 | 19.02243655 | CS |
| 260 | 7.45 | 107.814761216 | 6.91 | 29.86 | 6.32 | 883162 | 18.81849321 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| NVDANVIDIA Corporation | US$ 128,99 (8,93%) | 567,37M |
| TNXPTonix Pharmaceuticals Holding Corporation | US$ 0,46005 (11,64%) | 381,46M |
| HEPAHepion Pharmaceuticals Inc | US$ 0,2192 (32,85%) | 314,81M |
| SLXNSilexion Therapeutics Corporation | US$ 1,335 (130,17%) | 237,62M |
| JBLUJetBlue Airways Corporation | US$ 6,01 (-25,71%) | 124,58M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
